Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study

Abstract

BackgroundPolycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet.ResultsFifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment.PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls.ConclusionOur pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan.Trial registrationClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered, .Electronic supplementary materialThe online version of this article (10.1186/s13048-019-0500-x) contains supplementary material, which is available to authorized users.

Serum metabolomic profile of symptomatic and asymptomatic SARS-CoV-2 infected patients 

“…Instrumental analyses were performed with a GC-MS system (GC-2010 Plus gas chromatograph and QP2010SE mass spectrometer; Shimadzu Corp., Kyoto, Japan). The analytical details are reported in Troisi et al [21][22][23][24][25][26].…”

A prospective study of metformin versus myoinositol plus d-chiroinositol combination therapy in polycystic ovarian syndrome

“…The results were consistent with the study conducted by Troisi et al, Ozay et al and Regidor et al presenting reduction in testosterone levels with the administration of myoinositol and d-chiroinositol. 8,11,12 Tiwari et al also observed similar trends in testosterone levels at 6 months in metformin group. 13 The mean random blood glucose at baseline was 108.84± 11.08 and 87.07±4.48 which decreased to 100.64±7.73 and 82.57±2.26 after final follow up at 9 months in group 1 and 2 respectively.…”

Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature

“…identified increased levels of lactic acid in lean and overweight PCOS women and decreased levels in obese PCOS women, suggesting an augmented muscle insulin-stimulated glucose use in lean, but not obese women with PCOS (19,20). This difference may indicate that IR might be more severe and extensive in obese patients (19,20).…”